This site is intended for patients in Great Britain (England, Scotland and Wales) who have been prescribed PIQRAY®▼ (alpelisib) + fulvestrant.

How does it work?

Piqray (alpelisib) is a targeted therapy taken with another medicine called fulvestrant1,2 to slow down cancer cell growth.2

Piqray works by blocking the effects of enzymes called phosphatidylinositol-3-kinases (PI3K). These enzymes help cancer cells to grow and multiply. By blocking their action, alpelisib can reduce growth and spread of the cancer and help to destroy cancer cells.2

Piqray in combination with fulvestrant may slow down breast cancer cell growth.2

Piqray infographic

Fulvestrant is a type of hormonal therapy that prevents oestrogen from attaching to cancer cells that are hormone receptor-positive (HR+). When these tumours can not use oestrogen to grow, their growth is slowed or stopped.3

For more information on your treatment, you can download the Piqray brochure which gives you more detailed information on starting, and staying on track with PIQRAY® and fulvestrant.

Need some support? Visit the dedicated page to find out where you can receive support 

Need support? >
Support, image of hands

Where would you like to go next?

Why have I been prescribed, doctor with clipboard

How do I take Piqray?

Find out more about how to take your medication correctly

Side effects, image showing a woman in bed

What side effects could I experience?

Learn about the possible side effects of taking Piqray and what to do

Abbreviations

aBC, advanced breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha.
 

References

  1. Faslodex (fulvestrant) Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/68/pil. [Accessed November 2021].
  2. PIQRAY® (alpelisib) Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/11684/pil. [Accessed November 2021].
  3. Patel HK, et al. Pharmacol Ther. 2018;186:1–24.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

UK | January 2022 | 147266